Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer

We conducted a phase I study of a weekly nab-paclitaxel and S-1 combination therapy in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. The primary objective was to estimate the maximum tolerated and recommended doses. Each treatment was repeated every 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsurutani, Junji, Kuroi, Katsumasa, Iwasa, Tsutomu, Miyazaki, Masaki, Nishina, Shinichi, Makimura, Chihiro, Tanizaki, Junko, Okamoto, Kunio, Yamashita, Toshinari, Aruga, Tomoyuki, Shigekawa, Takashi, Komoike, Yoshifumi, Saeki, Toshiaki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471786/
https://www.ncbi.nlm.nih.gov/pubmed/25786335
http://dx.doi.org/10.1111/cas.12658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471786/
https://www.ncbi.nlm.nih.gov/pubmed/25786335
http://dx.doi.org/10.1111/cas.12658

Ejemplares similares